<DOC>
	<DOCNO>NCT00627536</DOCNO>
	<brief_summary>This study undertaken investigate scar-improvement efficacy safety single dose avotermin ( Juvista ) injection skin incision .</brief_summary>
	<brief_title>Scar-Improvement Efficacy Safety Single Intradermal Injection Avotermin ( Juvista ) Administered Following Full-Thickness Skin Incisions</brief_title>
	<detailed_description />
	<mesh_term>Cicatrix</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Males female age 1885 year give write informed consent . Subjects body mass index within 15 35 kg/m2 . Subjects clinically acceptable result laboratory test Female subject child bear potential use acceptable method ( ) contraception . Subjects history evidence hypertrophic keloid scarring . Subjects tattoo previous scar within 3cm area incise . Subjects prior surgery area incise within one year first dosing day . Subjects history bleed disorder ; receive anticoagulant antiplatelet therapy . Subjects evidence past present clinically significant disease may affect endpoint trial . Subjects clinically significant skin disorder chronic currently active . Subjects clinically significant medical condition history would impair wound heal . Subjects history drug hypersensitivity drug dressing use trial . Subjects take , take investigational product participate clinical trial three month prior first trial dose administration . Subjects take regular , continuous , oral corticosteroid therapy . Subjects undergoing investigation change management exist medical condition . Subjects history drug abuse , positive drug abuse test cocaine , amphetamine , metamphetamines , opiates benzodiazepine screen period . Subjects consider unlikely complete trial whatever reason . Subjects clinically significant neurological impairment disease . Subjects active infection . Subjects pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>scarring , Juvista , avotermin , transform growth factor beta 3 , TGFB3</keyword>
</DOC>